Category: Regulatory DisclosuresBy adminApril 15, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:EGX Disclosure regarding Rameda’s Governance ReportNextNext post:Rameda launches initiative for the complementary dispensary and home delivery of medication at no cost, underlining its dedication to ensuring the healthcare and safety of some of Egypt’s most immune-compromised patient populations amid the COVID-19 pandemicRelated PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
